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Biofilm formations play an important role in Staphylococcus aureus pathogenesis and
contribute to antibiotic treatment failures in biofilm-associated infections. The aim of
this study was to evaluate the pharmacokinetic/pharmacodynamic (PK/PD) profiles of
cefquinome against an experimental catheter-related biofilm model due to S. aureus,
including three clinical isolates and one non-clinical isolate. The minimal inhibitory
concentration (MIC), minimal biofilm inhibitory concentration (MBIC), biofilm bactericidal
concentration (BBC), minimal biofilm eradication concentration (MBEC) and biofilm
prevention concentration (BPC) and in vitro time-kill curves of cefquinome were studied
in both planktonic and biofilm cells of study S. aureus strains. The in vivo post-
antibiotic effects (PAEs), PK profiles and efficacy of cefquinome were performed in
the catheter-related biofilm infection model in murine. A sigmoid Emax model was
utilized to determine the PK/PD index that best described the dose-response profiles
in the model. The MICs and MBICs of cefquinome for the four S. aureus strains
were 0.5 and 16 μg/mL, respectively. The BBCs (32–64 μg/mL) and MBECs (64–
256 μg/mL) of these study strains were much higher than their corresponding BPC
values (1–2 μg/mL). Cefquinome showed time-dependent killing both on planktonic
and biofilm cells, but produced much shorter PAEs in biofilm infections. The best-
correlated PK/PD parameters of cefquinome for planktonic and biofilm cells were the
duration of time that the free drug level exceeded the MIC (fT > MIC, R2 = 96.2%)
and the MBIC (fT > MBIC, R2 = 94.7%), respectively. In addition, the AUC24h/MBIC
of cefquinome also significantly correlated with the anti-biofilm outcome in this model
(R2 = 93.1%). The values of AUC24h/MBIC for biofilm-static and 1-log10-unit biofilm-
cidal activity were 22.8 and 35.6 h; respectively. These results indicate that the PK/PD
profiles of cefquinome could be used as valuable guidance for effective dosing regimens
treating S. aureus biofilm-related infections.
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INTRODUCTION
Bioﬁlm-related infections are major medical problems and
are usually refractory to antibiotic therapy (Costerton
et al., 1999). The treatment failures in clinical cases are
consistently reported by both clinician and veterinarians
(Fabres-Klein et al., 2015). Staphylococcus aureus is a pathogen
commonly associated with bioﬁlm-related infections such
as endocarditis, osteomyelitis, prosthetic joint infections,
and catheter-related infections (Parra-Ruiz et al., 2012).
Antibiotics that are eﬀective against planktonic bacteria
often do not prove satisfactory in eradicating bioﬁlms, as
bioﬁlm cells are physiologically distinct from non-adherent
and planktonic cells (Widmer et al., 1990). S. aureus cells
within bioﬁlm are signiﬁcantly resistant to host defense
systems as well as the antimicrobial therapy (Begun et al.,
2007). The poor therapeutic outcome may be due to slow
bacterial growth rate, limited penetration of the antibiotic
and the presence of persister cells (e.g., small-colony variants)
within the bioﬁlm matrix (Davies et al., 1998). Therefore,
there is a growing need for new approaches to optimize
antibiotic regimens in vivo for the treatment of bioﬁlm-related
infections.
Cefquinome is a fourth generation cephalosporin which
used widely in the veterinary industry with antimicrobial
activity against a broad spectrum of Gram-positive and -
negative bacterial species, and is regarded as highly stable to
β-lactamases (CVMP, 1995). The PK/PD proﬁles of antibiotics
could provide an important approach to establish more-
eﬀective treatment strategies and to predict the antimicrobial
eﬃcacies (Craig, 1998). However, most previous PK/PD studies
were focused on planktonic cells and very limited results
regarding bioﬁlm infections were reported (Shan et al.,
2014). The extrapolation of these results to bioﬁlm cells
was problematic for predicting an eﬃcient doing regimen
in bioﬁlm-related infections (Blaser et al., 1995). Therefore,
in the present study, we evaluated the in vivo PK/PD
proﬁles of cefquinome against an experimental catheter-
related bioﬁlm infection model in murine due to three
clinical S. aureus isolates and one non-clinical S. aureus
isolate.
MATERIALS AND METHODS
Antibiotics and Bacterial Strains
Cefquinome was pharmaceutical grade and purchased from
Qilu Animal Health Products Co., Ltd. (Jinan, China). Three
veterinary clinical isolates from the endocarditis cases [One
methicillin-susceptible S. aureus (MSSA; S45) and two
methicillin-resistant S. aureus (MRSA; M4 and M21)], and
one non-clinical isolate (MSSA; F27) were included in the
present study. All S. aureus strains were identiﬁed by MALDI-
TOF MS system (Axima-Assurance-Shimadzu). For MRSA
isolates, the 16S rRNA and mecA genes were detected using a
multiplex PCR assay. MRSA strain ATCC 43300 served as a
control.
In Vitro Susceptibility Testing and Biofilm
Susceptibility Assay
The minimal inhibitory concentrations (MICs) of cefquinome
against planktonic S. aureus cells were determined using standard
Clinical and Laboratory Standards Institute (CLSI) microdilution
method (CLSI, 2008). The minimal bioﬁlm inhibitory
concentrations (MBICs), bioﬁlm bactericidal concentrations
(BBCs), minimal bioﬁlm eradication concentrations (MBECs),
and bioﬁlm prevention concentrations (BPCs) of cefquinome
for bioﬁlms were determined using the Calgary Bioﬁlm Device
as previously reported (Ceri et al., 1999; Moskowitz et al., 2004;
Fernandez-Olmos et al., 2012; Macia et al., 2014; Details in
Supplementary Material).
In Vitro Time-Kill Curves
The in vitro time-kill curves were determined as previously
described (Zhao et al., 2014). In brief, cefquinome was
added into MH broth containing approximately 5 × 105
CFU/mL exponentially growing S. aureus cells to obtain drug
concentrations of 0, 0.5, 1, 2, 4, 8, and 16 × MIC, and incubated
at 37◦C for 24 h. Samples were removed at 0, 3, 6, 9, 12, and 24 h
after incubation and then subjected to 10-fold serial dilutions.
Twenty-ﬁve microliter of each dilution was then plated onto
quadrants of MH agar and incubated at 37◦C for 24 h for viable
counts enumeration. Results were expressed as log10 CFU/mL
and the limit of detection was 40 CFU/mL.
Biofilm Formation Assay
Stationary phase of S. aureus cells were resuspended in
physiological NaCl solution to an OD650nm of 0.5 (∼108
CFU/mL) and diluted 1:100 into Brain Heart Infusion (BHI)
broth supplemented with 0.5% glucose (Seidl et al., 2008). The
96-well plate was inoculated with 200 μL of this suspension
and incubated for 18 h at 37◦C. Subsequently, the wells were
rinsed twice to remove planktonic cells. Bioﬁlm was stained with
crystal violet (0.1% in distilled water) for 1 min and washed with
PBS three times. After visual observation, the adhering dye was
dissolved with 75% alcohol to quantify the biomass measuring
optical density at 650 nm.
Experimental Catheter-Associated
Biofilm Infection Model in Murine
The animals used for the in vivo experiments were 6-week-
old (24–27 g) and pathogen-free female ICR mice (Guangdong
Medical Lab Animal Center, Guangzhou, China). Animals were
maintained in accordance with the American Association for
Accreditation of Laboratory Animal Care criteria. All animal
experiments were approved by Animal Research Committees of
South China Agricultural University.
The catheter-associated bioﬁlm infection in a murine model
was established as previously described (Kadurugamuwa et al.,
2003). Brieﬂy, 1-cm segments of 14-gage Teﬂon intravenous
catheter (Abbocath-T; Burns Vet Supply, Vancouver, WA, USA)
were infected by study S. aureus strains in 3 mL of BHI broth
supplemented with 0.5% glucose. After 6–8 h incubation at 37◦C,
the infected catheters were washed twice with PBS to remove
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TABLE 1 | In vitro susceptibility testing and biofilm susceptibility assays of
cefquinome vs. Staphylococcus aureus isolates used in this study.
S. aureus Strains Cefquinome (µg/mL) Oxacillin mecA
MIC§ MBIC† BBC MBEC BPC MIC
S45 (MSSA) 0.5 16 64 256 2 0.125 ND
F27 (MSSA) 0.5 16 32 64 1 0.125 ND
M4 (MRSA) 0.5 16 64 128 2 16 +
M21 (MRSA) 0.5 16 32 64 1 16 +
ND, not determined. §MIC, minimal inhibitory concentration of cefquinome for
planktonic cells; †MBIC, minimal biofilm inhibitory concentration, defined as the
lowest concentration of drug that inhibited visible biofilm growth in the recovery
medium (Moskowitz et al., 2004); BBC, biofilm bactericidal concentration, defined
as the lowest concentration that killed 99.9% of the biofilm cells (Fernandez-
Olmos et al., 2012); MBEC, minimal biofilm eradication concentration, defined
as the minimal concentration of antibiotic required to eradicate the biofilm (0
CFU/peg on plate counts; Ceri et al., 1999); BPC, biofilm prevention concentration,
determined using a modification of MBIC assay in which bacterial inoculation and
drug exposure occur simultaneously (Fernandez-Olmos et al., 2012).
unbound bacteria, and then implanted subcutaneously on each
side of each mouse. Our preliminary data demonstrated that the
infected catheter contained ∼5 × 105 CFU/catheter (data not
shown). At speciﬁc time points, tissue ﬂuid (planktonic cells)
was aspirated around each catheter segment and plated on MH
agar plates for CFU determination. At sacriﬁce, catheters were
removed from the subcutaneous tunnels and rinsed twice with
PBS. Subsequently, the catheters were transferred to a separate
tube containing 1 ml of sterile PBS. The tubes were placed in
an ultrasonic bath (100 W, 40 kHz) and sonicated for 10 min,
followed by vortexing for 1 min to remove bioﬁlm cells from the
catheter surface. The disaggregated bioﬁlm was then processed to
quantify the number of viable cells in the suspension.
Pharmacokinetics
The animals were administrated intramuscularly using varying
doses of cefquinome (2, 8, 16, 32, 64, 128, or 256 mg/kg;
six animals/group) as a single administration at 24 h after
catheter implantation. Blood samples were collected by retro-
orbital puncture following time points: 0, 0.08, 0.17, 0.25,
0.5, 0.75, 1, 2, 3, 4, and 6 h after antibiotic administration.
Plasma was immediately isolated by centrifugation at 3000 × g
for 10 min at 4◦C, and drug concentrations in plasma were
determined using a HPLC-ESI-MS/MS method as described
previously (Zhou et al., 2015). The limit of quantiﬁcation
(LOQ) and detection were 0.01 and 0.005 μg/mL, respectively.
The time-concentration curves of cefquinome were best ﬁtted
to a one-compartment model with ﬁrst-order absorption. PK
parameters including half-lives of ﬁrst-order absorption (T1/2Ka)
and elimination (T1/2Kel), volume of distribution during the
terminal phase as a function of bioavailability (Vd/F), total area
under time-concentration curve (AUC), body clearance as a
function of bioavailability (Cl/F), the peak plasma concentration
(Cmax) and the time of maximum concentration (Tmax) were
conducted using WinNonlin software (version 6.1, Pharsight,
St. Louis, MO, USA). The bioavailability (F) was calculated as
F% = (AUCi.m./AUCi.v.) × 100% (F = 98.3%, intravenous PK
FIGURE 1 | In vitro time-kill curves and in vivo treatment efficacies of
cefquinome against planktonic and biofilmMRSA-M4 cells in a
catheter-associated infection model after a single intramuscular dose
of cefquinome (MIC = 0.5 µg/mL). (A) Cefquinome versus planktonic
bacteria in vitro; (B) Cefquinome versus planktonic bacteria in vivo;
(C) Cefquinome versus biofilm bacteria in vivo.
data not shown). The time courses of multiple administrations in
PK/PD analysis were extrapolated from the corresponding single
dose PK data obtained in the present study. The protein blinding
of cefquinome in mouse was previously reported (7.4%; Wang
et al., 2014). In addition, cefquinome PKs in healthy animals were
also determined as reference.
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FIGURE 2 | (A) Biofilm formation assays of S. aureus strains. Performed biofilm was stained with 0.1% crystal violet. (B) Quantification (OD650nm) of S. aureus
biofilm formations. Results represent the mean of three independent experiments. Error bars indicate the standard deviation. ∗P < 0.01 for S45 and M4 strains
versus M21 or F21 strains.
TABLE 2 | PK parameters of cefquinome after a single intramuscular administration in catheter-associated biofilm infection model of mice.
Cefquinome (mg/kg) T1/2Kel† (h) T1/2Ka (h) Tmax (h) Cmax (µg/mL) AUC (µg/mL) × h Vd/F (L/kg) Cl/F (L/kg × h)
2 0.33 0.02 0.10 3.02 1.79 0.54 1.12
8 0.31 0.04 0.15 10.1 6.25 0.57 1.28
16 0.22 0.06 0.16 22.2 11.8 0.43 1.36
32 0.35 0.03 0.12 35.6 22.7 0.71 1.41
64 0.30 0.03 0.11 67.2 37.9 0.74 1.69
128 0.47 0.04 0.17 178.5 165.1 0.57 0.78
256 0.48 0.05 0.19 287.6 331.1 0.73 0.75
Mean ± SD 0.38 ± 0.14 0.04 ± 0.01 0.14 ± 0.03 – – 0.61 ± 0.11 1.20 ± 0.32
†T1/2Kel, elimination half-life; T1/2Ka, absorption half-life; Cmax, peak plasma concentration; Tmax, time of maximum concentration; AUC, total area under the time-
concentration curve; Vd/F, volume of distribution during terminal phase as a function of bioavailability; Cl/F, body clearance as a function of bioavailability.
In Vivo Efficacy of Cefquinome in
Planktonic and Biofilm Bacteria and PAEs
To evaluate the in vivo eﬃcacy of cefquinome in the experimental
catheter-related bioﬁlm model caused by a representative MRSA
strain, M4, animals were treated with a single intramuscular
dose of cefquinome (8–256 mg/kg) at 24 h after infection. The
control groups received physiological NaCl. At 0, 3, 6, 9, 12,
and 24 h post-dosing, animals were sacriﬁced and tissue ﬂuid
around the catheter was collected for planktonic bacterial culture.
In addition, the catheter segments were removed aseptically, and
sonicated for 10 min as described above, then quantitatively
cultured. MRSA densities were expressed as mean log10 CFU/mL
and log10 CFU/catheter ±SD for in tissue ﬂuid and bioﬁlm;
respectively.
The post-antibiotic eﬀect (PAE) was calculated with the
equation: PAE = T – C, where T is the time for the mean growth
of 1 log10 CFU in planktonic or bioﬁlm bacteria of treated mice
after free drug levels in plasma fell below theMIC orMBIC, andC
is the corresponding time for the untreated control mice (Spivey,
1992).
PD Parameter Determination in
Catheter-Associated Biofilm Infection
Model
To evaluate the regimens of cefquinome, including dose
levels as well as dosing intervals, in planktonic and bioﬁlm
TABLE 3 | PAE durations of cefquinome against MRSA-M4 after a single
dose of administration in catheter-associated biofilm infection model of
mice.
Cefquinome (mg/kg) T > MIC (h) T >MBIC(h) PAE duration (h)
Planktonic† Biofilm∗
8 1.9 – 0.6 –
16 3.1 0.28 0.9 -0.5
32 4.8 0.47 1.8 -0.2
64 6.0 0.75 2.3 0.6
128 8.7 3.16 3.8 0.3
256 11.5 4.38 5.3 0.7
†A positive relationship between cefquinome dosing and PAEs in planktonic cells
(R2 = 94.9%); *P < 0.01 for PAEs of MRSA biofilm versus planktonic cells.
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TABLE 4 | Integration of PK/PD indices of cefquinome against planktonic and biofilm bacteria in S. aureus catheter-associated biofilm infection model of
mice (MRSA-M4).
Cefquinome (mg/kg) Planktonic Biofilm∗
T > MIC Cmax/MIC AUC/MIC T > MBIC Cmax/MBIC AUC/MBIC
2 1.2 6.1 3.6 – 0.19 0.11
8 1.9 20.2 12.5 – 0.63 0.39
16 3.1 44.5 23.6 0.28 1.39 0.74
32 4.8 71.1 45.4 0.47 2.22 1.42
64 6.0 134.3 75.8 0.75 4.20 2.37
128 8.7 357.1 330.3 3.16 11.2 10.3
256 11.5 575.1 662.2 4.38 17.9 20.7
∗P < 0.05 for PK/PD indices of biofilm versus planktonic cells.
bacteria, the anesthetized mice infected with catheter segments
carrying ∼5 × 105 CFU S. aureus were treated at 24 h
after implantation with single or multiple intramuscular
administration of cefquinome. Treatment regimens included
total doses ranging from 2 to 512 mg/kg/day administered
using twice-daily and once-daily. An untreated group received
physiological NaCl intramuscularly. All groups of mice were
sacriﬁced after 24 h of therapy. The catheter segments were
removed and tissue ﬂuid was collected for CFU determination as
described above.
PK/PD Modeling and Data Analysis
For PK/PD integration of cefquinome in planktonic and bioﬁlm
bacteria, the surrogate indices the duration of time that free
drug level exceed the MIC or MBIC (T > MIC or MBIC),
Cmax/MIC or MBIC and AUC from 0 to 24 h (AUC24h)/MIC
or MBIC, were calculated for each animal. The numbers of
bacteria in planktonic cells and bioﬁlms were correlated to these
PK/PD indices for each of the dosing regimens studied. The
in vivo PK/PD analysis was performed using the inhibitory
sigmoid dose-eﬀect model derived from the following formula:
E = E0 + Emax × CeN/(EC50 iN + CeN ), where E0 is the change
in log10 CFU/mL of untreated controls (absence of drug), Emax
is the maximal antibacterial eﬀect determined as the diﬀerence
in log10 CFU/mL, EC50 is the value of the target PK/PD index
required to achieve 50% of Emax, Ce is the target PK/PD indices
(T > MIC or MBIC, Cmax /MIC or MBIC and AUC24h/MIC
or MBIC), and N is the Hill coeﬃcient that described the slope
of dose eﬀect curve (Aliabadi et al., 2003). The correlation
between the eﬃcacy and each of these PK/PD indices was
calculated using the non-linear WinNonlin regression program
(version 6.1, Pharsight; Gebru et al., 2009). R2 was used to
estimate the variance of regression with each of the PK/PD
parameters.
To further compare the antibacterial eﬃcacy of cefquinome
between planktonic and bioﬁlm cells, the sigmoid dose-response
model derived from the Hill equation also was used to
calculate the target values of cefquinome that produced the
bacteriostatic action, 0.5-log10-unit and 1-log10-unit of the net
bactericidal eﬀect over 24 h (bioﬁlm-static, 0.5-log10-unit and
1-log10-unit bioﬁlm-cidal values, respectively; Zhang et al.,
2014).
RESULTS
In Vitro Susceptibility Testing and Biofilm
Susceptibility Assays
The bioﬁlm susceptibility of the four S. aureus isolates is shown
inTable 1. TheMICs and BPCs of cefquinome for the four strains
used in this study were nearly identical (0.5 and 1–2 μg/mL,
respectively), indicating that cefquinome has high antibacterial
activity in vitro against planktonic S. aureus cells and potential
ability on preventing of early bioﬁlm formations. The MBICs
(16 μg/mL), BBCs (32–64 μg/mL) and MBECs (64–256 μg/mL)
of cefquinome against the study S. aureus strain cells within
bioﬁlms were signiﬁcantly higher than their corresponding MIC
values. None of these parameters correlated with the methicillin-
resistance status of these strains.
In Vitro Time-Kill Curves
The in vitro time-kill curves of cefquinome against planktonic
MRSA-M4 were illustrated in Figure 1A. In vitro killing proﬁles
demonstrated a time- and concentration- dependent feature.
Persisting inhibition of planktonic bacterial growth was observed
when S. aureus was exposed to cefquinome at a concentration
of 0.5 μg/mL. At 2 × MIC and all higher concentrations of
cefquinome, either bactericidal eﬀect or elimination of S. aureus
(3- or 4-log10-units reduction) was observed during 12–24 h of
incubation, while less than 12 h of incubation was insuﬃcient to
eliminate all bacteria.
In Vitro Biofilm Formation Assays
All study strains possessed the ability to form bioﬁlms.
Interestingly, MRSA-M4 and MSSA-S45 strains formed
signiﬁcantly greater bioﬁlms as compared to MRSA-M21 or
MSSA-F21 strain (P < 0.01; Figure 2). However, based on the
OD650nm values (OD > 2 × OD of media control; 0.2), the
MRSA-M21 and MSSA-F21 strains were considered as the strong
bioﬁlm producers (Jin et al., 2006). No signiﬁcant diﬀerence was
observed between MRSA-M4 and MSSA-S45 bioﬁlms.
Pharmacokinetics of Cefquinome
The PK parameters of cefquinome in the representative S. aureus
strain M4 infected mice after a single intramuscular dose of
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FIGURE 3 | Relationships between the change in log10 number of CFU for MRSA-M4 and PK/PD parameters of cefquinome. Each symbol represents
the data from each catheter segment or tissue fluid. (A) T > MIC; (B) Cmax/MIC; (C) AUC24h/MIC; (D) T > MBIC; (E) Cmax/MBIC; (F) AUC24h/MBIC. The R2 value is
the determination coefficient. Data points below the horizontal line represent killing and points above the horizontal line represent growth. Planktonic cells, filled
diamonds; biofilms, and open squares.
2–256 mg/kg are shown in Table 2. The drug was absorbed and
eliminated according to a one-compartmental model with ﬁrst-
order absorption (Supplementary Figure S1). A dose dependency
was observed for Cmax and AUC values of cefquinome with
ranges of from 3.02 to 287.6μg/mL and 1.79 to 331.1μg× h/mL,
respectively. The Tmax varied from 0.10 to 0.19 h with a mean of
0.14 h. The elimination half-life (T1/2Kel) of cefquinome ranged
from 0.22 to 0.48 h. We also demonstrated that there were
no signiﬁcant cefquinome PK diﬀerences between healthy and
infected animals with diﬀerent S. aureus strains (PK data in
healthy animals not shown).
Antimicrobial Efficacy of Cefquinome
and PAEs In Vivo
As expected, the in vivo activity of cefquinome exhibited time-
dependent features both on planktonic cells and on bioﬁlm
formations. However, a higher cefquinome administration was
acquired to suppress the regrowth of bioﬁlms. The dosage
Frontiers in Microbiology | www.frontiersin.org 6 January 2016 | Volume 6 | Article 1513
Zhou et al. PK/PD Evaluation of Cefquinome Against S. aureus Biofilm
TABLE 5 | PK/PD model parameter estimates and target values of cefquinome for T > MIC or MBIC required to achieve the various antibacterial
efficacies against a representative MRSA isolates M4 in planktonic or in catheter-associated biofilm infection model.
Parametersand cell type Emax†(log10 CFU/mL) E0(log10 CFU/mL) EC50 (h) Static (h) 0.5-log10 drop (h) 1.0-log10 drop (h)
Planktonic (T > MIC) –5.64 3.11 6.61 7.25 8.61 10.4
Biofilm (T > MIC)∗∗ –4.40 2.16 17.4 17.6 19.7 22.7
Biofilm (T > MBIC)∗ –3.57 2.13 5.42 6.17 7.35 8.76
†Emax is the maximal drug effect of cefquinome against biofilm bacteria; E0, difference in number of biofilm bacteria (CFU/mL) in untreated group between time 0 and
24 h; EC50 is the T > MIC or MBIC value required to achieve 50% of the Emax; ∗P < 0.05 for T > MBIC in biofilm versus in planktonic cells; **P < 0.01 for T > MIC in
biofilm versus in planktonic cells.
regimen of cefquinome at 256 mg/kg inhibited the planktonic
cells for 24 h, but regrowth was observed in the bioﬁlm
infections at the same time point (Figures 1B,C). Importantly,
an approximately 3-log10 CFU reduction occurred for planktonic
cells, while about 1.5 log10 CFU increased in the bioﬁlm
infection following 12 h treatment with cefquinome at 256 mg/kg
(Figures 1B,C).
A positive relationship between cefquinome dosing and PAEs
was seen in planktonic S. aureus cells (R2 = 94.9%). However, less
than 1 h PAE with the dose range of cefquinome (8–256 mg/kg)
was demonstrated for the bioﬁlm cells (Table 3). Therefore,
signiﬁcant longer PAE of planktonic S. aureus cells was observed
as compared to bacteria cells within bioﬁlms (P < 0.01; Table 3).
PK/PD Parameters Integration and
Determination
Integration of PK/PD indices of cefquinome with planktonic and
bioﬁlm bacteria are showed in Table 4. The PK/PD parameters
of planktonic cells were signiﬁcantly greater as compared with
the PK/PD proﬁles of bioﬁlm when single doses of cefquinome
at 2–256 mg/kg were administrated (P < 0.05; Table 4). For
instance, T > MICs were ranged from 1.2 to 11.5 h, but the
T>MBICs were from 0.28 to 4.38 h. In addition, Cmax/MICs and
Cmax/MBICs were from 6.1 to 575.1 and 0.19 to 17.9; respectively.
More importantly, the AUC/MICs were signiﬁcantly larger than
AUC/MBICs (3.6–662 h vs. 0.11–20.7 h).
The relationship of the change of CFU and the PK/PD
parameters of cefquinome between planktonic and bioﬁlm cells
was shown in Figure 3. T > MIC was the PK/PD index that
best correlated with antimicrobial eﬃcacy for planktonic cells
(R2 = 96.2%; Figure 3A). However, for bioﬁlm infections, the
T > MBIC index (R2 = 94.7%) showed a better correlation
than the T > MIC (R2 = 91.9%; Figures 3A,D). Interestingly,
the AUC/MIC parameter exhibited a strong correlation with the
in vivo eﬃcacy of cefquinome for bioﬁlm cells (R2 = 91.1%), but a
poor correlation for planktonic bacteria (R2 = 68.6%; Figure 3C).
PK/PD Model Parameter Estimates for
the Target Efficacy Against Study
Isolates
The PK/PD indices and the corresponding target values
of cefquinome required to achieve various eﬃcacies against
S. aureus M4 in planktonic cells and bioﬁlm infections are
listed in Table 5. The EC50 value of cefquinome was 6.61 h for
planktonic cells versus 17.4 h for a bioﬁlm infection (P < 0.01).
The 1-log10-unit reduction eﬀect of cefquinome required value
of T > MIC at least 10.4 h for planktonic cells, but 22.7 h for
bioﬁlm formations (T>MBIC; 8.76 h;Table 5). The in vivo dose-
eﬀect relationship of cefquinome for three additional strains of
S. aureus in both planktonic and bioﬁlm cells were also calculated
using the inhibitory sigmoid Emax model and a similar result was
observed (Supplementary Table S1).
In order to predict an eﬀective dose, we determined the dose-
response relationships between PK/PD index (AUC24h/MBIC)
and the in vivo eﬃcacy of cefquinome. The dose response
curve strongly correlated with the AUC24h/MBIC index for all
study S. aureus bioﬁlm infections (R2 = 93.1%; Supplementary
Figure S2). The target values of cefquinome necessary to produce
a bioﬁlm-static action and a 1-log10-unit bioﬁlm-cidal action
as well as the corresponding AUC24h/MBIC index values were
listed in Table 6. The mean values of AUC24h/MBIC associated
with stasis and 1-log10-unit reduction were 22.8 and 35.6 h;
respectively.
DISCUSSION
In this study, an experimental catcher-associated bioﬁlm murine
infection model was developed for evaluation of the PK/PD
proﬁles of cefquinome against S. aureus, including MSSA and
MRSA strains, growing as planktonic cells and within bioﬁlms.
To the best of our knowledge, the present study represents the
TABLE 6 | In vivo pharmacokinetics and pharmacodynamics model of
cefquinome against a S. aureus catheter-associated biofilm infection
using AUC24h/MBIC as the predictive PK-PD index (all study S. aureus
strains included).
Biofilm PK-PD Parameters (units) Mean values SD
Emax (log10 CFU/mL)† –3.31 0.17
E0 (log10 CFU/mL) 1.95 0.09
EC50 (h) 20.3 0.15
Slope (N) 3.92 0.79
AUC24h/MBIC for biofilm-static action (h) 22.8 1.46
AUC24h/MBIC for 1-log10-unit biofilm-cidal action (h) 35.6 5.74
†Emax is the maximal drug effect of cefquinome against biofilm bacteria; E0,
difference in number of biofilm bacteria (CFU/mL) in untreated group between time
0 and 24 h; EC50 is the AUC24h/MBIC value required to achieve 50% of the Emax;
N, slope of AUC24h/MBIC-response curve; AUC24h/MBIC for biofilm-static action,
values which produced E = 0 (no change in bacterial count after 24 h treatment).
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ﬁrst time PK/PD evaluation of cefquinome in vivo in S. aureus
bioﬁlm-related infections.
Several key insights emerged from this study. First, we
investigated in vivo PAEs of cefquinome in a catheter-related
bioﬁlm infection model due to S. aureus, including MSSA and
MRSA strains, and observed that the PAEs in bioﬁlms showed
signiﬁcantly shorter than those in planktonic cells (Table 3).
It is well accepted that the importance of long PAEs for
optimizing treatment regimens in clinical practice (Spivey, 1992).
Thus, longer PAE is positively correlated with greater S. aureus
counts reduction in the catheter-related bioﬁlm model which
is consistent with previous reports (den Hollander et al., 1998;
Ahmad et al., 2015). For instance, a recent study developed in
a neutropenic mouse thigh model demonstrated that exposure
of planktonic S. aureus ATCC 29213 cells to cefquinome led to
a visibly longer PAE of 2.9 h as compared to below 1 h PAE
observed in vitro (Wang et al., 2014). Similarly, another study
also proved that the longer in vitro PAE could achieve a better
in vivo treatment eﬃcacy in a rabbit meningitis model (Tauber
et al., 1984).
In addition, we demonstrated that cefquinome was fairly
eﬀective, causing ∼2- to 3-log10 CFU reductions for planktonic
cells but only ∼1.0- to 1.5-log10 CFU reductions for bioﬁlm
cells within the catheter. This observation proved that higher
concentrations and longer treatment times of cefquinome are
requested to kill S. aureus cells within bioﬁlm as compared with
planktonic cells in the catheter-associated bioﬁlm infections in
murine duo to S. aureus strains. Unfortunately, the treatment
strategies aimed at eradicating bioﬁlm cells was not achievable
in the present model, even at the highest dosing regimen
(256 mg/kg; q12h). The lack of the antimicrobial eﬃcacy for
bioﬁlm-related infections may be related to intrinsic tolerance of
bioﬁlm-grown bacterial populations to antibiotics, as well as the
poor penetration of cefquinome through extracellular polymeric
matrix of bioﬁlm formations and inadequate antibiotic-exposure
for bacterial cells embedded in bioﬁlms (Macia et al., 2014). Other
mechanisms such as the contributions of matrix components
and chromosomal β-lactamase increases may also lead to this
resistance (Hengzhuang et al., 2013).
It is notable that we were able to take advantage of the PK/PD
parameters to optimize the in vivo eﬃcacy against planktonic
cells, as well as bioﬁlm infections in the catheter-related bioﬁlm
model. The dose-response proﬁles of cefquinome for planktonic
and bioﬁlm cells showed the best correlation with T > MIC
and T > MBIC; respectively (R2, 96.2% for planktonic cells and
94.7% for bioﬁlms; Figures 3A,D). More recently, Wang et al.
(2014) investigated the pharmacodynamics of cefquinome for
planktonic MRSA infections and also noted that the same index
(T>MIC) correlated the best with treatment eﬃcacy in a murine
thigh infection model. In our study, although the T > MBIC
index exhibited the best correlation, the AUC/MIC of cefquinome
was signiﬁcantly correlated with bioﬁlm killing (R2 = 91.1%) as
compared to planktonic cell infections (R2 = 68.6%; Figure 3C).
This was almost equivalent with the correlation of the T > MIC
for bioﬁlms (R2 = 91.9%). Interestingly, the AUC/MBIC index
which is based on the antibiotic susceptibility assay of bioﬁlms
showed a signiﬁcant correlation with the in vivo eﬃcacy
for all study S. aureus bioﬁlm cells infections (R2 = 93.1%).
Additionally, considering the higher dosage and longer the
treatment periods required to treat bioﬁlm infections in vivo, our
results suggest that the AUC/MBIC would be the recommended
predictive PK/PD index in computation of dosing regimens for
S. aureus bioﬁlm-related infections.
The development of device-related bioﬁlm infections is
correlated with the density of adherent cells on the implant
surfaces (Joo and Otto, 2012). Once the bacterial density
increases and the colony changes to bioﬁlm formation, the
eradication is virtually impossible in vivo (Fernandez-Olmos
et al., 2012). Therefore, the important treatment strategy for
bioﬁlm-producing bacteria is to prevent the progression of early
bioﬁlm formation instead of ﬁnding a ﬁnal dosing regimen for
eradication of the mature bioﬁlms. In this study, the BPCs of
cefquinome for all study S. aureus isolates were only slightly
higher than their MICs, which is an interesting parameter that
could be used with the aim of reducing the cell density to
prevent bioﬁlm formation (Macia et al., 2014). More importantly,
the present PK/PD model on S. aureus bioﬁlms provided an
AUC24h/MBIC ratio of 35.6 h that could theoretically predict
1-log10 CFU bioﬁlm-cidal eﬀect. These results in conjunction
with BPC90 data of S. aureus bioﬁlms may provide an additional
approach to the design of dosing regimens that prevent the early
stages of bioﬁlms caused by planktonic S. aureus cells during
antibiotic treatment. Additionally, a recent study also showed
that daptomycin and rifampin alone and in combination were
successful in preventing S. aureus bioﬁlm infections at the early
stages in a subcutaneous rat pouch model (Cirioni et al., 2010).
For the treatment of bioﬁlm infections, more frequent
administrations are needed to obtain a longer treatment period
in form of T > MBIC. However, it is usually impractical
to administer drug more frequently in the veterinary clinical
trials. Routinely, once-daily or twice-daily schedule is considered
a good compliance target. Furthermore, cefquinome (and the
majority of β-lactams in general) have short elimination half-
lives and the limitations are obvious with this routine dosing
strategy (Turnidge, 1998). Thus, new formulations of cefquinome
with prolonged half-life proﬁles should be developed to achieve a
better therapeutic outcome in bioﬁlm-related infections.
Our investigations have several limitations. For example, only
four representative S. aureus strains were evaluated in this study.
Thus, the results need to be veriﬁed in a larger population of
strains. In addition, the combination regimens were not tested
against S. aureus bioﬁlm infections model. Studies to deﬁne
the eﬃcacy of antibiotic combinations in the same catheter-
related bioﬁlmmodel are ongoing in our laboratory. Nonetheless,
this is the ﬁrst study to our best knowledge to demonstrate
PK/PD relationships of cefquinome against MSSA and MRSA
growing as planktonic and bioﬁlm cells in an in vivo experimental
catcher-associated bioﬁlm infection model. In the present study,
cefquinome showed time-dependent activities against S. aureus
bioﬁlms in vitro as well as in vivo. In addition, signiﬁcantly
shorter PAEs were observed on bioﬁlms vs. planktonic cells.
The PK/PD index of cefquinome that best correlated with
anti-bioﬁlm eﬃcacy was the T > MBIC in this study. More
importantly, the AUC/MBIC of cefquinome also signiﬁcantly
Frontiers in Microbiology | www.frontiersin.org 8 January 2016 | Volume 6 | Article 1513
Zhou et al. PK/PD Evaluation of Cefquinome Against S. aureus Biofilm
correlated with therapeutic outcomes for bioﬁlm-related
infections. These results could potentially provide a new
perspective for establishing appropriate strategies of antibiotic
treatment in S. aureus bioﬁlm related formation.
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